

**LIST OF REFERENCES CITED BY APPLICANT**

(See separate sheets if necessary)

ATTY. DOCKET NO.

10271-116-999

APPLICATION NO.

10/657,006

APPLICANT

Dingivan et al.

FILING DATE

September 5, 2003

ART UNIT

1644

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A151	2003/0185824	10/02/03	Vaishnaw et al.	
	A152	2004/0170635	09/02/04	Vaishnaw et al.	
	A153	2004/0265305	12/30/04	Vaishnaw et al.	

**FOREIGN PATENT DOCUMENTS**

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B71	WO 02/060480	08/08/02	Biogen, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C228	BIMALANGSHU et al., 2005, "Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation," Br. J. Haematol. 128:351-359	
	C229	KOENECKE et al., 2003, "NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507," Exp. Hematol. 31(10):911-23	
	C230	NIZET et al., 1999, "Apoptosis of human naive NK cells mediated by a rat IgG2b anti CD2 mAb through a fractricidal ADCC reaction," Immunol. Lett. 68(2-3):229-35	
	C231	SHAFFER et al., 2005, "Fludarabine treatment is associated with depletion of host CD4+CD25<sup>HIGH</sup>, FOXP3+, CTLA-4+ cells and increased incidences of full donor chimerism and GVHD in non-myeloablative haploidentical hematopoietic cell transplant recipients," 47th Annual Meeting of the American Society of Hematology, Abstract, 2898	
	C232	SPITZER et al., 2003, "Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies," Transplantation 75(10):1748-51	
	C233	SPITZER et al., 2005, "In vivo and ex vivo T-cell depleted (TCD) nonmyeloablative haploidentical stem cell transplantation (NSCT) for hematologic malignancy (HM)," 47th Annual Meeting of the American Society of Hematology, Abstract, 4731	
	C234	VILLARD et al., 2006, "High percentage of CD4+CD25high expressing FOXP3 and CTLA4 characterized recipient of haploidentical hematopoietic cell transplantation with low T cell recovery," Annual Meeting of the Swiss Society for Allergy and Immunology, Abstract, S33	
	C235	YEE et al., 2005, "Minimal HLA disparity and KIR ligand compatibility in host versus graft direction may facilitate donor engraftment following in vivo and ex vivo T cell depleted (TCD) nonmyeloablative haploidentical stem cell transplantation for hematologic malignancies," 47th Annual Meeting of the American Society of Hematology, Abstract, 3668	
	C236	ZHANG et al., 2003, "Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /Z.S./

NY-3943249-VI

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>10271-116-999</b>	APPLICATION NO. <b>10/657,006</b>
	APPLICANT <b>Dingivan et al.</b>	
	FILING DATE <b>September 5, 2003</b>	ART UNIT <b>1644</b>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		CD2 monoclonal antibody, MEDI-507," Blood 102(1):284-8	

<b>EXAMINER</b> /Zachary Skelding/	<b>DATE CONSIDERED</b> 02/18/2008
---------------------------------------	--------------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH~~ /Z.S./